ScinoPharm, the Taiwan-based CMO/CRO, will spend $37.6 million to expand its China operation. The company is building a plant in Tainan Science Park to manufacture high potency cytotoxic compounds that will be used in injectable treatments for cancer. Previously, ScinoPharm specialized in intermediates, APIs and small-batch production of drugs for clinical trials. More details.... Stock Symbol: (TWSE: 1789) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});